In utero exposure to valproic acid and autism - A current review of clinical and animal studies

Neurotoxicology and Teratology

Volumn 36, Issue , 2013, Pages 47-56

  Roullet, Florence I ^a   Lai, Jonathan K Y ^a   Foster, Jane A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti epileptic drugs; Autism; Behavior; Neurodevelopment; Pregnancy registries; Teratogen

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; NEUROLIGIN; VALPROIC ACID;

AUTISM; BEHAVIOR DISORDER; COGNITION; CONGENITAL MALFORMATION; EMBRYOPATHY; EMBRYOTOXICITY; EPILEPSY; FETUS OUTCOME; FETUS RISK; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; HIGH RISK INFANT; HUMAN; NERVE CELL LESION; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PERINATAL PERIOD; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANIMALS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; VALPROIC ACID;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 84875666213     PISSN: 08920362     EISSN: 18729738     Source Type: Journal    
DOI: 10.1016/j.ntt.2013.01.004     Document Type: Review

References (90)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorder (DSM-IV), Washington, DC 1994.
2. Betancur C., Sakurai T., Buxbaum J.D. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci 2009, 32:402-412.
3. Bromley R.L., Mawer G., Clayton-Smith J., Baker G.A. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008, 71:1923-1924.
4. Casanova M.F., Buxhoeveden D.P., Brown C. Clinical and macroscopic correlates of minicolumnar pathology in autism. J Child Neurol 2002, 17:692-695.
5. CDC Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. MMWR 2012, 61:1-19.
6. Chen Y.H., Chiou H.Y., Lin H.C., Lin H.L. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol 2009, 66:979-984.
7. Christianson A.L., Chesler N., Kromberg J.G. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Dev Med Child Neurol 1994, 36:361-369.
8. Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev 2004, 10:248-258.
9. Cummings C., Stewart M., Stevenson M., Morrow J., Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011, 96:643-647.
10. Dufour-Rainfray D., Vourc'h P., Le Guisquet A.M., Garreau L., Ternant D., Bodard S., et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett 2010, 470:55-59.
11. Fombonne E. Epidemiological trends in rates of autism. Mol Psychiatry 2002, 7(Suppl. 2):S4-S6.
12. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 2003, 33:365-382.
13. Frisch C., Husch K., Angenstein F., Kudin A., Kunz W., Elger C.E., et al. Dose-dependent memory effects and cerebral volume changes after in utero exposure to valproate in the rat. Epilepsia 2009, 50:1432-1441.
14. Fuller L.C., Cornelius S.K., Murphy C.W., Wiens D.J. Neural crest cell motility in valproic acid. Reprod Toxicol 2002, 16:825-839.
15. Gandal M.J., Edgar J.C., Ehrlichman R.S., Mehta M., Roberts T.P., Siegel S.J. Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry 2010, 68:1100-1106.
16. Glickman G. Circadian rhythms and sleep in children with autism. Neurosci Biobehav Rev 2010, 34:755-768.
17. Go H.S., Seo J.E., Kim K.C., Han S.M., Kim P., Kang Y.S., et al. Valproic acid inhibits neural progenitor cell death by activation of NF-kappaB signaling pathway and up-regulation of Bcl-XL. J Biomed Sci 2011, 18:48.
18. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978.
19. Grafodatskaya D., Chung B., Szatmari P., Weksberg R. Autism spectrum disorders and epigenetics. J Am Acad Child Adolesc Psychiatry 2010, 49:794-809.
20. Harden C.L., Hopp J., Ting T.Y., Pennell P.B., French J.A., Allen Hauser W., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1229-1236.
21. Harden C.L., Meador K.J., Pennell P.B., Hauser W.A., Gronseth G.S., French J.A., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1237-1246.
22. Harden C.L., Pennell P.B., Koppel B.S., Hovinga C.A., Gidal B., Meador K.J., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1247-1255.
23. Idring S., Rai D., Dal H., Dalman C., Sturm H., Zander E., et al. Autism spectrum disorders in the Stockholm Youth Cohort: design, prevalence and validity. PLoS One 2012, 7:e41280.
24. Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 2000, 22:319-324.
25. Jentink J., Loane M.A., Dolk H., Barisic I., Garne E., Morris J.K., et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
26. Kataoka S., Takuma K., Hara Y., Maeda Y., Ago Y., Matsuda T. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int J Neuropsychopharmacol 2011, 1-13.
27. Kim K.C., Kim P., Go H.S., Choi C.S., Yang S.I., Cheong J.H., et al. The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. Toxicol Lett 2011, 201:137-142.
28. Kolozsi E., Mackenzie R.N., Roullet F.I., Decatanzaro D., Foster J.A. Prenatal exposure to valproic acid leads to reduced expression of synaptic adhesion molecule neuroligin 3 in mice. Neuroscience 2009, 163:1201-1210.
29. Kou Y., Betancur C., Xu H., Buxbaum J.D., Ma'ayan A. Network- and attribute-based classifiers can prioritize genes and pathways for autism spectrum disorders and intellectual disability. Am J Med Genet C Semin Med Genet 2012, 160C:130-142.
30. Kulaga S., Sheehy O., Zargarzadeh A.H., Moussally K., Berard A. Antiepileptic drug use during pregnancy: perinatal outcomes. Seizure 2011, 20:667-672.
31. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999, 58:31-59.
32. Marinova Z., Ren M., Wendland J.R., Leng Y., Liang M.H., Yasuda S., et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009, 111:976-987.
33. Markram K., Rinaldi T., La Mendola D., Sandi C., Markram H. Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 2008, 33:901-912.
34. Mawhinney E., Campbell J., Craig J., Russell A., Smithson W., Parsons L., et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important?. Seizure 2012, 21:215-218.
35. Meador K. Valproate poses risk to unborn child. Epilepsy Curr 2005, 5:116-117.
36. Meador K.J. Effects of in utero antiepileptic drug exposure. Epilepsy Curr 2008, 8:143-147.
37. Meador K., Reynolds M.W., Crean S., Fahrbach K., Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008, 81:1-13.
38. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
39. Meador K.J., Baker G.A., Browning N., Cohen M.J., Clayton-Smith J., Kalayjian L.A., et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011, 134:396-404.
40. Mehta M.V., Gandal M.J., Siegel S.J. mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. PLoS One 2011, 6:e26077.
41. Meunier H., Carraz G., Neunier Y., Eymard P., Aimard M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie 1963, 18:435-438.
42. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009, 2:95-109.
43. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 2004, 3:287-302.
44. Nadebaum C., Anderson V., Vajda F., Reutens D., Barton S., Wood A. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 2011, 17:133-142.
45. Nadebaum C., Anderson V.A., Vajda F., Reutens D.C., Barton S., Wood A.G. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 2011, 76:719-726.
46. Nakamura K., Sekine Y., Ouchi Y., Tsujii M., Yoshikawa E., Futatsubashi M., et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 2010, 67:59-68.
47. Nakasato A., Nakatani Y., Seki Y., Tsujino N., Umino M., Arita H. Swim stress exaggerates the hyperactive mesocortical dopamine system in a rodent model of autism. Brain Res 2008, 1193:128-135.
48. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002, 52:576-579.
49. Narita M., Oyabu A., Imura Y., Kamada N., Yokoyama T., Tano K., et al. Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. Neurosci Res 2010, 66:2-6.
50. Okada A., Kushima K., Aoki Y., Bialer M., Fujiwara M. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res A Clin Mol Teratol 2005, 73:229-238.
51. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?. Reprod Toxicol 2009, 28:1-10.
52. Peckman H. The U.S. Food and Drug Administration (FDA) has assigned pregnancy category D to valproate. N C Med J 2010, 71:396-398.
53. Pennell P.B. Pregnancy in women who have epilepsy. Neurol Clin 2004, 22:799-820.
54. Pohl-Guimaraes F., Krahe T.E., Medina A.E. Early valproic acid exposure alters functional organization in the primary visual cortex. Exp Neurol 2011, 228:138-148.
55. Rasalam A.D., Hailey H., Williams J.H., Moore S.J., Turnpenny P.D., Lloyd D.J., et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005, 47:551-555.
56. Rinaldi T., Perrodin C., Markram H. Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic acid animal model of autism. Front Neural Circuits 2008, 2:4.
57. Rinaldi T., Silberberg G., Markram H. Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. Cereb Cortex 2008, 18:763-770.
58. Rodier P.M., Ingram J.L., Tisdale B., Nelson S., Romano J. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J Comp Neurol 1996, 370:247-261.
59. Rodier P.M., Ingram J.L., Tisdale B., Croog V.J. Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol 1997, 11:417-422.
60. Roullet F.I., Crawley J.N. Mouse models of autism: testing hypotheses about molecular mechanisms. Curr Top Behav Neurosci 2011, 7:187-212.
61. Roullet F.I., Wollaston L., Decatanzaro D., Foster J.A. Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. Neuroscience 2010, 170:514-522.
62. Schain R.J., Freedman D.X. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961, 58:315-320.
63. Scherer S.W., Dawson G. Risk factors for autism: translating genomic discoveries into diagnostics. Hum Genet 2011, 130:123-148.
64. Schneider T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
65. Schneider T., Turczak J., Przewlocki R. Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 2006, 31:36-46.
66. Schneider T., Roman A., Basta-Kaim A., Kubera M., Budziszewska B., Schneider K., et al. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 2008, 33:728-740.
67. Scott L.J., Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007, 9:343-354.
68. Shallcross R., Bromley R.L., Irwin B., Bonnett L.J., Morrow J., Baker G.A. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011, 76:383-389.
69. Snow W.M., Hartle K., Ivanco T.L. Altered morphology of motor cortex neurons in the VPA rat model of autism. Dev Psychobiol 2008, 50:633-639.
70. Stanton M.E., Peloso E., Brown K.L., Rodier P. Discrimination learning and reversal of the conditioned eyeblink reflex in a rodent model of autism. Behav Brain Res 2007, 176:133-140.
71. Sui L., Chen M. Prenatal exposure to valproic acid enhances synaptic plasticity in the medial prefrontal cortex and fear memories. Brain Res Bull 2012, 87:556-563.
72. Tashiro Y., Oyabu A., Imura Y., Uchida A., Narita N., Narita M. Morphological abnormalities of embryonic cranial nerves after in utero exposure to valproic acid: implications for the pathogenesis of autism with multiple developmental anomalies. Int J Dev Neurosci 2011, 29:359-364.
73. Tomson T., Battino D. Antiepileptic treatment in pregnant women: morphological and behavioural effects. Handb Exp Pharmacol 2011, 205:295-315.
74. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, 10:609-617.
75. Tsujino N., Nakatani Y., Seki Y., Nakasato A., Nakamura M., Sugawara M., et al. Abnormality of circadian rhythm accompanied by an increase in frontal cortex serotonin in animal model of autism. Neurosci Res 2007, 57:289-295.
76. Tung E.W., Winn L.M. Epigenetic modifications in valproic acid-induced teratogenesis. Toxicol Appl Pharmacol 2010, 248:201-209.
77. US Food and Drug Administration Information for healthcare professionals: risk of neural tube birth defects following prenatal exposure to valproate [http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm, December 3, 2009. [cited March 13, 2012]].
78. US Food and Drug Administration Valproate products: drug safety communication - risk of impaired cognitive development in children exposed in utero (during pregnancy) [http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm261610.htm, June 30, 2011. [cited March 13, 2012]].
79. Vajda F.J., Hitchcock A., Graham J., O'Brien T., Lander C., Eadie M. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007, 47:468-474.
80. Vajda F.J., Hollingworth S., Graham J., Hitchcock A.A., O'Brien T.J., Lander C.M., et al. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurol Scand 2010, 121:89-93.
81. Vajda F.J., Horgan D., Hollingworth S., Graham J., Hitchcock A.A., Roten A., et al. The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol 2012, 52:49-53.
82. Veenstra-VanderWeele J., Muller C.L., Iwamoto H., Sauer J.E., Owens W.A., Shah C.R., et al. Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci U S A 2012, 109:5469-5474.
83. Wagner G.C., Reuhl K.R., Cheh M., McRae P., Halladay A.K. A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate. J Autism Dev Disord 2006, 36:779-793.
84. Walcott E.C., Higgins E.A., Desai N.S. Synaptic and intrinsic balancing during postnatal development in rat pups exposed to valproic acid in utero. J Neurosci 2011, 31:13097-13109.
85. Werler M.M., Ahrens K.A., Bosco J.L., Mitchell A.A., Anderka M.T., Gilboa S.M., et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol 2011, 21:842-850.
86. Williams P.G., Hersh J.H. A male with fetal valproate syndrome and autism. Dev Med Child Neurol 1997, 39:632-634.
87. Williams G., King J., Cunningham M., Stephan M., Kerr B., Hersh J.H. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001, 43:202-206.
88. Wohr M., Roullet F.I., Crawley J.N. Reduced scent marking and ultrasonic vocalizations in the BTBR T+tf/J mouse model of autism. Genes Brain Behav 2011, 10:35-43.
89. Yu I.T., Park J.Y., Kim S.H., Lee J.S., Kim Y.S., Son H. Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation. Neuropharmacology 2009, 56:473-480.
90. Zhang Y., Sun Y., Wang F., Wang Z., Peng Y., Li R. Downregulating the canonical Wnt/beta-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress. Neurochem Res 2012, 37:1409-1419.